Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RRM2 | P31350 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15007 | 0.78 | KDM4E (0.61) | KDM4EL3MBTL1BTKRRM2 | |
| SCHEMBL924155 | 0.76 | ESR1 (0.43) | THRATHRBESR1ALDH1A1 | |
| SCHEMBL19735731 | 0.74 | KDM4E (0.45) | THRBKDM4EL3MBTL1ALDH1A1PKM | |
| SCHEMBL11010879 | 0.74 | KDM4E (0.39) | KDM4EL3MBTL1BTKRRM2 | |
| SCHEMBL2133032 | 0.74 | KDM4E (0.43) | KDM4EL3MBTL1BTKRRM2 | |
| SCHEMBL2622782 | 0.74 | RRM2 (0.50) | KDM4EL3MBTL1BTKRRM2 | |
| SCHEMBL14059886 | 0.74 | KDM4E (0.39) | KDM4EL3MBTL1BTKRRM2 | |
| SCHEMBL14878746 | 0.74 | KDM4E (0.39) | KDM4EL3MBTL1BTKRRM2 | |
| SCHEMBL11124858 | 0.74 | ALDH1A1 (0.41) | KDM4EL3MBTL1BTKALDH1A1RRM2 | |
| SCHEMBL10245415 | 0.74 | ESR1 (0.45) | THRATHRBESR1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109686-A1 | ISOINDOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109686-A1 | ISOINDOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRD1, OPRL1 | THRA 521/4885THRB 419/4885ESR1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.